lactobionic acid has been researched along with sorafenib in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Altamura, E; Azzariti, A; Cutrignelli, A; Denora, N; Di Fonte, R; Franco, M; Iacobazzi, RM; Laquintana, V; Lopalco, A; Lopedota, AA; Porcelli, L | 1 |
| Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G | 1 |
| Coelho, JFJ; Faneca, H; Mendonça, PV; Santo, D; Serra, AC | 1 |
3 other study(ies) available for lactobionic acid and sorafenib
| Article | Year |
|---|---|
Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.
Topics: Asialoglycoprotein Receptor; Dendrimers; Disaccharides; Drug Carriers; Fluorescein-5-isothiocyanate; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chitosan; Delayed-Action Preparations; Disaccharides; Drug Synergism; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Lung Neoplasms; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Porosity; Rats; Silicon Dioxide; Sorafenib; Triterpenes; Ursolic Acid | 2017 |
Targeted downregulation of MYC mediated by a highly efficient lactobionic acid-based glycoplex to enhance chemosensitivity in human hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; RNA, Small Interfering; Sorafenib | 2023 |